The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss, offering a revolutionary approach to patients worldwide. Although the hormone glucose-dependent insulinotropic polypeptide (GIP) was already shown by Helmholtz Munich scientists to decrease body weight via the brain GIP receptor, the ...
Tirzepatide is a recently approved treatment for type-2 diabetes. Treatment with tirzepatide decreases body weight while improving glucose metabolism in patients with obesity and type-2 diabetes. Although the drug is designed to activate receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), the contribution of activating the GIP receptor in the overall efficacy of ...
Iphofen (ots) - The Knauf Group is supporting the Romanian government’s energy-saving and renovation offensive by substantially expanding its local plant capacity. The Knauf Insulation Group unit is building another insulation plant next to its current site in Tarnaveni, north of Sibiu. Together with the expansion ...
Geneva (ots/PRNewswire) - The Global Fund collaborates with the Johnson & Johnson Foundation and the Skoll Foundation to Launch the Africa Frontline First Catalytic Fund - Private sector investments to the Global Fund's Africa Frontline First Catalytic Fund from the Johnson & Johnson Foundation and the Skoll Foundation totaling US$ 25 million. - The Global Fund to ...
company: Klöckner & Co SE Am Silberpalais 1 D-47057 Duisburg phone: +49(0)203-307-0 FAX: +49(0)203-307-5000 mail: info@kloeckner.de WWW: http://www.kloeckner.de sector: Metal Goods & Engineering ISIN: DE000KC01000 indexes: CDAX, Classic All Share, Prime All Share stockmarkets: free trade: Berlin, München, ...
